|
|
|
CVN Mouse Model for Alzheimer’s Disease Research Studies
A new tool for the study of Alzheimer’s disease, the CVN mouse displays amyloid plaques in the hippocampus at 9 months as well as behavioral and biochemical deficits characteristics of the disease. Learn more...
With an aging population and an increase of central nervous system diseases after the age of 65, there is a mounting need to discover and develop more innovative and effective therapeutic treatments focused on the central nervous system.
Charles River offers a wide range of services supported by our scientific depth, unique technical capabilities and experience in all the major neurodegenerative diseases and neurological indications, such as Alzheimer’s disease, Parkinson’s disease, chronic pain, epilepsy, Multiple Sclerosis, stroke, and more. From animal models of disease to preclinical testing, we have developed the tools to assist clients in shortening the development cycle of compounds with neurological implications.
|
|
|
|
|
CNS, central nervous system, nervous system, neurodegenerative, neurological, Alzheimer’s, Alzheimer’s disease, Parkinson’s, Parkinson’s disease, epilepsy, Multiple Sclerosis, MS, Neurobehavioral, neuropathology, neurotoxicology
Central Nervous System (CNS) | Drug Research, Discovery & Development | Charles River
From early discovery to preclinical testing and clinical trials, we can assist clients in shortening the development cycle of compounds to treat neurological disorders such as Alzheimer’s disease, Parkinson’s disease, epilepsy, and Multiple Sclerosis.